• Something wrong with this record ?

Nitrated fatty acids suppress angiotensin II-mediated fibrotic remodelling and atrial fibrillation

TK. Rudolph, T. Ravekes, A. Klinke, K. Friedrichs, M. Mollenhauer, M. Pekarova, G. Ambrozova, H. Martiskova, JJ. Kaur, B. Matthes, A. Schwoerer, SR. Woodcock, L. Kubala, BA. Freeman, S. Baldus, V. Rudolph,

. 2016 ; 109 (1) : 174-84. [pub] 20151123

Language English Country England, Great Britain

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000852

AIM: Atrial fibrosis, one of the most striking features in the pathology of atrial fibrillation (AF), is promoted by local and systemic inflammation. Electrophilic fatty acid nitroalkenes, endogenously generated by both metabolic and inflammatory reactions, are anti-inflammatory mediators that in synthetic form may be useful as drug candidates. Herein we investigate whether an exemplary nitro-fatty acid can limit atrial fibrosis and AF. METHODS AND RESULTS: Wild-type C57BL6/J mice were treated for 2 weeks with angiotensin II (AngII) and vehicle or nitro-oleic acid (10-nitro-octadec-9-enoic acid, OA-NO2, 6 mg/kg body weight) via subcutaneous osmotic minipumps. OA-NO2 significantly inhibited atrial fibrosis and depressed vulnerability for AF during right atrial electrophysiological stimulation to levels observed for AngII-naive animals. Left atrial epicardial mapping studies demonstrated preservation of conduction homogeneity by OA-NO2. The protection from fibrotic remodelling was mediated by suppression of Smad2-dependent myofibroblast transdifferentiation and inhibition of Nox2-dependent atrial superoxide formation. CONCLUSION: OA-NO2 potently inhibits atrial fibrosis and subsequent AF. Nitro-fatty acids and possibly other lipid electrophiles thus emerge as potential therapeutic agents for AF, either by increasing endogenous levels through dietary modulation or by administration as synthetic drugs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000852
003      
CZ-PrNML
005      
20170116093002.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/cvr/cvv254 $2 doi
024    7_
$a 10.1093/cvr/cvv254 $2 doi
035    __
$a (PubMed)26598510
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rudolph, Tanja K $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
245    10
$a Nitrated fatty acids suppress angiotensin II-mediated fibrotic remodelling and atrial fibrillation / $c TK. Rudolph, T. Ravekes, A. Klinke, K. Friedrichs, M. Mollenhauer, M. Pekarova, G. Ambrozova, H. Martiskova, JJ. Kaur, B. Matthes, A. Schwoerer, SR. Woodcock, L. Kubala, BA. Freeman, S. Baldus, V. Rudolph,
520    9_
$a AIM: Atrial fibrosis, one of the most striking features in the pathology of atrial fibrillation (AF), is promoted by local and systemic inflammation. Electrophilic fatty acid nitroalkenes, endogenously generated by both metabolic and inflammatory reactions, are anti-inflammatory mediators that in synthetic form may be useful as drug candidates. Herein we investigate whether an exemplary nitro-fatty acid can limit atrial fibrosis and AF. METHODS AND RESULTS: Wild-type C57BL6/J mice were treated for 2 weeks with angiotensin II (AngII) and vehicle or nitro-oleic acid (10-nitro-octadec-9-enoic acid, OA-NO2, 6 mg/kg body weight) via subcutaneous osmotic minipumps. OA-NO2 significantly inhibited atrial fibrosis and depressed vulnerability for AF during right atrial electrophysiological stimulation to levels observed for AngII-naive animals. Left atrial epicardial mapping studies demonstrated preservation of conduction homogeneity by OA-NO2. The protection from fibrotic remodelling was mediated by suppression of Smad2-dependent myofibroblast transdifferentiation and inhibition of Nox2-dependent atrial superoxide formation. CONCLUSION: OA-NO2 potently inhibits atrial fibrosis and subsequent AF. Nitro-fatty acids and possibly other lipid electrophiles thus emerge as potential therapeutic agents for AF, either by increasing endogenous levels through dietary modulation or by administration as synthetic drugs.
650    _2
$a akční potenciály $x účinky léků $7 D000200
650    _2
$a angiotensin II $x farmakologie $7 D000804
650    _2
$a zvířata $7 D000818
650    _2
$a fibrilace síní $x prevence a kontrola $7 D001281
650    _2
$a remodelace síní $x účinky léků $7 D064752
650    _2
$a transdiferenciace buněk $x účinky léků $7 D054338
650    _2
$a kultivované buňky $7 D002478
650    _2
$a konexin 43 $x analýza $7 D018031
650    _2
$a fibróza $7 D005355
650    _2
$a srdeční síně $x patologie $7 D006325
650    _2
$a kyseliny linolové $x farmakologie $7 D008041
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a dusíkaté sloučeniny $x farmakologie $7 D009574
650    _2
$a protein Smad2 $x antagonisté a inhibitory $7 D051899
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ravekes, Thorben $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
700    1_
$a Klinke, Anna $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany International Clinical Research Center-Center of Biomolecular and Cellular Engineering, St Anne's University Hospital Brno, Brno, Czech Republic.
700    1_
$a Friedrichs, Kai $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
700    1_
$a Mollenhauer, Martin $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
700    1_
$a Pekarova, Michaela $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic.
700    1_
$a Ambrozova, Gabriela $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic. $7 gn_A_00005405
700    1_
$a Martiskova, Hana $u Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic.
700    1_
$a Kaur, Jatinder-Jit $u Department of Cardiology, University Heart Center Hamburg, University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Matthes, Bianca $u Department of Cardiology, University Heart Center Hamburg, University Hospital Eppendorf, Hamburg, Germany.
700    1_
$a Schwoerer, Alex $u Department of Cellular and Integrative Physiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany DZHK (German Centre for Cardiovascular Research)-Hamburg/Kiel/Luebeck, Hamburg, Germany.
700    1_
$a Woodcock, Steven R $u Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
700    1_
$a Kubala, Lukas $u International Clinical Research Center-Center of Biomolecular and Cellular Engineering, St Anne's University Hospital Brno, Brno, Czech Republic Institute of Biophysics, Academy of Sciences of the Czech Republic, v. v. I, Brno, Czech Republic.
700    1_
$a Freeman, Bruce A $u Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA.
700    1_
$a Baldus, Stephan $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
700    1_
$a Rudolph, Volker $u Department of Cardiology, University Heart Center Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany volker.rudolph@uk.koeln.de.
773    0_
$w MED00009440 $t Cardiovascular research $x 1755-3245 $g Roč. 109, č. 1 (2016), s. 174-84
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26598510 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170116093107 $b ABA008
999    __
$a ok $b bmc $g 1179992 $s 961419
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 109 $c 1 $d 174-84 $e 20151123 $i 1755-3245 $m Cardiovascular Research $n Cardiovasc Res $x MED00009440
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options